The company has signed two separate agreements with the Agency for Science, Technology, and Research (A*STAR) and the Nanyang Technological University (NTU) to progress its therapeutic stem cell pipeline.
Plasticell, a biotech company specializing in the development of stem cell technologies and cell-based therapies, has signed two separate agreements with the Agency for Science, Technology, and Research (A*STAR) and the Nanyang Technological University (NTU) to progress its therapeutic stem cell pipeline. The agreements cover technology licensing, collaborative research, and scientific exchange visits.
Plasticell will initially collaborate with the laboratories of Professor Peter Dröge (School of Biological Sciences, NTU) and Dr. Farid Ghadessy (p53Lab, A*STAR) to apply proprietary genome editing technology to insert functional multi-transgene cassettes into specific loci of human stem cell lines. Plasticell will use the engineered lines in multiple projects focused on precisely directed stem cell differentiation, phenotypic screening for drug discovery, and in next-generation immuno-oncology applications.
Source:
